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Previewshave to eagerly wait for further studies
of DTP3 in other NF-kB-dependent hema-
tological malignancies and solid tumors
that overexpress GADD45b. Hopefully,
these studies will also pave the way for
the development of other approaches for
curtailing the survival activity of NF-kB in
GADD45b-negative cancers.
REFERENCES
De Smaele, E., Zazzeroni, F., Papa, S., Nguyen,
D.U., Jin, R., Jones, J., Cong, R., and Franzoso,
G. (2001). Nature 414, 308–313.DiDonato, J.A., Mercurio, F., and Karin, M. (2012).
Immunol. Rev. 246, 379–400.
Greten, F.R., Arkan, M.C., Bollrath, J., Hsu, L.C.,
Goode, J., Miething, C., Go¨ktuna, S.I., Neuenhahn,
M., Fierer, J., Paxian, S., et al. (2007). Cell 130,
918–931.
Karin, M., Cao, Y., Greten, F.R., and Li, Z.W.
(2002). Nat. Rev. Cancer 2, 301–310.
Lin, A., and Karin, M. (2003). Semin. Cancer Biol.
13, 107–114.
Lu, B., Ferrandino, A.F., and Flavell, R.A. (2004).
Nat. Immunol. 5, 38–44.Cancer Cell 26Papa, S., Zazzeroni, F., Bubici, C., Jayawardena,
S., Alvarez, K., Matsuda, S., Nguyen, D.U., Pham,
C.G., Nelsbach, A.H., Melis, T., et al. (2004). Nat.
Cell Biol. 6, 146–153.
Staudt, L.M. (2010). Cold Spring Harb. Perspect.
Biol. 2, a000109.
Tang, G., Minemoto, Y., Dibling, B., Purcell, N.H.,
Li, Z., Karin, M., and Lin, A. (2001). Nature 414,
313–317.
Tornatore, L., Sandomenico, A., Raimondo, D.,
Low, C., Rocci, A., Tralau-Stewart, C., Bua, M.,
Jaxa-Chamiec, A., Thotakura, A., Dyson, J., et al.
(2014). Cancer Cell 26, this issue, 495–508.5-Aza-CdR Delivers a Gene Body BlowSivakanthan Kasinathan1,2,3 and Steven Henikoff1,4,*
1Basic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
2Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA
3Molecular & Cellular Biology Graduate Program, University of Washington, Seattle, WA 98195, USA
4Howard Hughes Medical Institute, Seattle, WA 98109, USA
*Correspondence: steveh@fhcrc.org
http://dx.doi.org/10.1016/j.ccell.2014.09.004
In this issue of Cancer Cell, Yang et al. describe a causal relationship between gene body methylation and
gene expression and a role for genic methylation in response to clinical DNA methylation inhibitors, which
suggests that the mechanism of action of these inhibitors includes gene body hypomethylation-induced
downregulation of cancer-associated genes.DNA cytosine methylation is an ancient
regulatory mechanism present in diverse
phylogenies, including vertebrates, plants,
and some fungi (Jones, 2012). Cytosine
methylation of CG dinucleotides by DNA
methyltransferases (DNMTs) in promoters
is associated with gene silencing, e.g., in
X chromosome inactivation and imprinting
(Jones,2012),andpromoterhypermethyla-
tion is thought tocontribute to aberrant reg-
ulatory programs in cancer (Shenker and
Flanagan, 2012). Within the last decade,
so-called ‘‘epigenetic’’ drugs have come
to the forewith U.S. Food andDrug Admin-
istration approval of cytidine analog DNMT
inhibitors such as 5-aza-2-deoxycytidine
(5-Aza-CdR) formyelodysplasticsyndrome
and acute myeloid leukemia. Excitingly,
studies have also hinted at the efficacy of
this mode of intervention in solid tumors
(Shenker and Flanagan, 2012), expanding
the utility of these chemotherapeutics be-
yond hematologic malignancies.Although promoter methylation, which
maintains a ‘‘closed’’ chromatin state that
impairs transcriptional initiation (Jones,
2012), has beenwell studied, less is known
about the role of methylation in gene
bodies. Intriguingly, unlike at promoters
where methylation is associated with
gene repression, genicmethylation is posi-
tively correlated with gene expression
(Figure 1A) (Maunakea et al., 2010; Varley
et al., 2013). It is thought that DNA methyl-
ation inhibitors cause promoter hypome-
thylationandsubsequentgene reactivation
(Shenker and Flanagan, 2012). However,
the effect of these drugs on gene body
methylation has not been extensively
studied.
In this issue of Cancer Cell, the work
of Yang et al. (2014) suggests a
causal relationship between gene body
methylation and gene expression and
expands the understanding of the
mechanism of action of cytidine analogcancer chemotherapeutics. They as-
sayed genome-wide methylation at
various time points after short treatment
of a dividing colon cancer cell line with
5-Aza-CdR, allowing interrogation of re-
methylation kinetics and the durability
of methylation changes upon drug with-
drawal (Figure 1A). A clustering approach
used to classify genomic regions into
groups with high and low remethylation
rates revealed that gene bodies were
rapidly remethylated compared to pro-
moters (Figure 1B). Furthermore, gene
body remethylation was correlated with
gene expression. Exploiting DNMT
knockout cell lines, the authors deter-
mined that DNMT3B is required for rapid
remethylation of gene bodies following
5-Aza-CdR treatment (Figure 1A). Both
DNA methylation and gene expression
were attenuated in DNMT3B deficient
cells following 5-Aza-CdR treatment,
suggesting that DNMT inhibitor-induced, October 13, 2014 ª2014 Elsevier Inc. 449
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Figure 1. Gene Body Methylation, Gene Expression, and DNA Methylation Inhibitors
(A) Promoter methylation is associated with gene silencing, while gene bodymethylation is correlated with
gene expression. Measurement of methylation at various time points after treatment with the DNA meth-
yltransferase (DNMT) inhibitor 5-aza-2-deoxycytidine (5-Aza-CdR) reveals that promoters and gene
bodies can be differentially remethylated. Rapid remethylation of genic regions is dependent on DNMT3B.
(B) Rapidly remethylated regions tend to be located in gene bodies and are enriched for c-MYC-regulated
genes. Upon demethylation, rapidly remethylated gene bodies acquire a chromatin signature that may
modulate transcription by altering nucleosome stability.
(C) Methylation of gene bodies may attenuate cryptic initiation from alternative promoters.
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Previewsgene body demethylation downregulates
gene expression.
This causal relationship between 5-Aza-
CdR-induced genic hypomethylation and
downregulation of gene expression is
particularly important in the context of
the observation that c-MYC-regulated
genes were overrepresented in the rapidly
remethylated gene set (Figure 1B). Slowly
remethylated regions tended to be de
novo methylated in primary tumors and
associated with tumor suppressor genes.
This raises the possibility that methylation
inhibitors buffer against c-MYC-asso-
ciated gene expression changes charac-
teristic of many cancers. Moreover, the
observed attenuation of ostensible house-
keeping functions upon 5-Aza-CdR treat-
ment might manifest as inhibition of cell
growth, consistent with an association be-
tween genic methylation and constitutive
expression (Coleman-Derr and Zilberman,
2012).
By examining histonemodifications and
distribution of the H2A.Z histone variant
in regions exhibiting rapid and slow reme-
thylation kinetics, Yang, et al. (2014)
defined the interplay between 5-Aza-CdR
treatment, gene body methylation, and
chromatin signatures. H3K36m3 is en-
riched in actively transcribedgenic regions450 Cancer Cell 26, October 13, 2014 ª2014where it is thought to suppress histone
turnover tomaintain transcriptional fidelity,
whereasH3K27m3 is amark of Polycomb-
associated silencing. Additionally, the dis-
tribution of H2A.Z, which is thought to
destabilize nucleosomes, is strikingly anti-
correlated with DNA methylation at pro-
moters in vertebrates and plants (Conerly
et al., 2010; Zilberman et al., 2008). Upon
DNMT depletion, gene bodies of rapidly
remethylated genes became slightly en-
riched for H2A.Z, while H3K36m3 was en-
riched independent of methylation level,
possibly implicating this mark in rapid re-
methylation. Slowly remethylated regions
were strongly enriched for H3K27m3 and
H2A.Z, consistent with antagonism be-
tween these chromatin features and DNA
methylation. Additionally, analysis of
selected genes showed that gene body
demethylation caused by 5-Aza-CdR was
associated with H2A.Z deposition, a
modest depletion of H3K36m3, and
increased chromatin accessibility (Fig-
ure 1B). Collectively, these results sug-
gest that genic demethylation by cytidine
analogs may influence transcription by
modulating nucleosome stability (Fig-
ure 1B) and that remethylation after drug
withdrawal is influenced by chromatin
context.Elsevier Inc.There are many hypotheses regarding
the function of gene body methylation.
For example, genic methylation might
regulate alternative promoters (Maunakea
et al., 2010). Alternatively, gene body
methylation might inhibit cryptic transcrip-
tion initiation events. In plants, cryptic initi-
ation was proposed to generate antisense
transcripts that base pair with mRNA
transcribed from the canonical transcrip-
tion start site (TSS), leading to double-
stranded RNA-mediated methylation and
silencing of the cryptic TSS (Tran et al.,
2005) (Figure 1C). Consistent with this
model, genic methylation is anticorrelated
with transcriptional noise in vertebrates
(Huh et al., 2013). It is attractive to hypoth-
esize that an increase in cryptic initiation
in active genes upon nucleosome desta-
bilization by methylation inhibitors leads
to DNMT3B recruitment and suppres-
sion of cryptic transcription by rapid
remethylation.
This work by Yang, et al. (2014) also
provides important insights into the
pharmacology of DNA methylation inhib-
itors. Despite the apparent lack of
specificity of methylation inhibitors, re-
methylation kinetics after drug with-
drawal are dependent on genomic and
chromatin contexts and driven by
DNMT3B. Promoter demethylation ap-
pears to be sustained after drug with-
drawal, while genic demethylation is
comparatively short-lived, which may
have implications for understanding clin-
ical responses to methylation inhibitors.
Mechanistically, DNA methylation inhibi-
tors may normalize gene expression in
cancer by reactivating silenced tumor
suppressors through their action at pro-
moters and buffer overexpression of
oncogenes and metabolic genes by hy-
pomethylating gene bodies.
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A recent article in Cell shows that vitamin D receptor activation reprograms reactive stroma in the tumor
microenvironment to a less inflammatory, quiescent state and is associated with increased drug retention,
tumor response, and survival in pancreatic cancer models. Stroma reprogramming, as opposed to ablation,
may emerge as a new treatment paradigm.It has been known for some time that
carcinomas are associated with a reac-
tive stroma microenvironment (Rønnov-
Jessen et al., 1996). Reactive stroma
usually initiates early in cancer progres-
sion, co-evolves with the cancer, and
represents a host response to disrupted
epithelial homeostasis. In effect, the
reactive stroma response is a rather
generic response, ostensibly to serve a
repair-centric function. The persistence
of this response is what is observed in
fibrosis disorders and during cancer
progression. Less clear are the specific
cell types, their origins, and how the
biology of reactive stroma affects tumor
progression. Collectively, this reactive
stroma has been referred to as carci-
noma-associated fibroblasts, myofibro-
blasts, or stellate cells (Apte et al.,
2004; Orimo and Weinberg, 2006; Von-
laufen et al., 2008). The majority of
studies have shown that reactive stroma
generaly promotes tumors, yet specific
mechanisms are not understood. The
biology affected by the stromal compart-
ment in cancer is likely to be quite
complex and involve a balance among
tumor-promoting and tumor-inhibiting
mechanisms. Nevertheless, the notion
of targeting the reactive stroma within
the tumor microenvironment as a meansof inhibiting cancer progression is an
attractive one.
Perhaps one of the most important per-
spectives regarding reactive stroma was
noted by Dvorak years ago, that cancers
are like ‘‘wounds that do not heal’’
(Dvorak, 1986). The biology of wound
repair is very complicated and is charac-
terized by pro-growth conditions that
require reactive stromal cells, followed
by a return to a normal differentiation
state. This process involves a resolution
of the reactive, pro-growth repair state
to one of more normal tissue quiescence
and biology. Hence, stromal reprogram-
ming is a part of normal wound repair
biology. If, as Dvorak pointed out, cancers
are like wounds that do not heal, then it
can be surmised that the stromal reprog-
ramming that instructs the stroma back
to differentiation during wound repair sim-
ply does not normally occur in cancer.
Considerable evidence in the literature
supports this concept, which is well out-
lined by Sherman et al. (2014) in a recent
issue of Cell. As aptly pointed out in
this article, in addition to tumor-pro-
moting functions, the persistent stromal
response has also been shown to inhibit
effective drug delivery and influence pat-
terns of therapeutic resistance in pancre-
atic cancer.Sherman et al. (2014) show that the
vitamin D receptor (VDR) is a critical
regulator of pancreatic stellate cells, the
reactive stroma observed in pancreatic
cancer. Importantly, this study shows
that VDR activation results in a reprog-
ramming of reactive stroma and reduced
inflammatory markers typically associ-
ated with fibrosis. In pancreatic tumor
models, this VDR-mediated stromal re-
programming resulted in increased drug
(gemcitabine) availability and reduced tu-
mor volume. Remarkably, use of the VDR
ligand resulted in a 57% increase in ani-
mal survival as compared to gemcitabine
treatment only. Effectively, this study
suggests that VDR activation resolves
the reactive stroma phenotype to one
that is noninflammatory and quiescent.
In essence, a reprogramming of the
stroma to a state more common of
normal homeostasis, such as would
occur naturally during completion of
normal wound healing. In this regard,
it would seem that VDR activation in
pancreatic cancer changes the tumor’s
status from being a wound that does
not heal, as cited by Dvorak, to a wound
that is partially healed in the important
stromal compartment.
The overall importance of the Sherman
et al. (2014) study is underscored by the, October 13, 2014 ª2014 Elsevier Inc. 451
